Update on Affibody molecules for in vivo imaging of targets for cancer therapy
2009 (English)In: Minerva biotecnologica (Testo stampato), ISSN 1120-4826, Vol. 21, no 1, 21-30 p.Article in journal (Refereed) Published
An increasing specificity of the cancer treatment requires an accurate detection of cancer-associated molecular targets to avoid over- and undertreatment. Radionuclide molecular imaging is a pronitising way for visualisation of such targets. Affibody molecules (Affibody (R) molecules), small (7 kDa) robust scaffold proteins constitute a new promising class of high-affinity molecular probes for in vivo molecular imaging. Pre-clinical studies demonstrated a great potential of derivatives of Z(HER2:342) Affibody molecule to visualise expression of HER2 in tumour xenografts. Robustness of the Affibody scaffold enabled labelling in harsh conditions without loosing specificity of the HER2-binding. This paper provides an overview of the recent development of Affibody molecules. During the recent year, an important achievement was the development of site-specific labelling of Affibody molecules providing well-characterised uniform conjugates with defined biodistribution and targeting properties. The site-specific labelling was obtained either by an incorporation of chelators during peptides synthesis of Affibody molecules or by an introduction of a single cysteine in the originally cysteine-free Affibody scaffold and the use of a thiol-directed coupling. A feasibility of modification of the biodistribution of Affibody molecules by different chelators was another interesting fmding. This was demonstrated during development of mercaptoacetyl-containing peptide based chelators for Tc-99m-labelling of Affibody molecules. Several positron-emitting labels enabled the use of advantages of PET for Affibody-mediated radionuclide imaging. it was demonstrated that the rapid targeting of Affibody molecules is compatible with the use of such labels as Ga-68 and F-18.
Place, publisher, year, edition, pages
2009. Vol. 21, no 1, 21-30 p.
Affibody molecules, Neoplams, Radiopharmaceuticals, Radionuclide imaging, HER2
Medical and Health Sciences
IdentifiersURN: urn:nbn:se:uu:diva-128331ISI: 000268685700003OAI: oai:DiVA.org:uu-128331DiVA: diva2:331274